Zacks Investment Research downgraded shares of Leap Therapeutics (NASDAQ:LPTX) from a buy rating to a hold rating in a report released on Thursday morning.
According to Zacks, “Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. “
Shares of Leap Therapeutics (LPTX) traded down $0.02 during trading hours on Thursday, hitting $6.30. 50,120 shares of the stock traded hands, compared to its average volume of 65,457. The stock has a market cap of $77.83 and a P/E ratio of -1.82. Leap Therapeutics has a twelve month low of $4.90 and a twelve month high of $10.10.
In other Leap Therapeutics news, COO Augustine Lawlor purchased 1,057,769 shares of Leap Therapeutics stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average price of $6.09 per share, for a total transaction of $6,441,813.21. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 58.40% of the stock is owned by corporate insiders.
About Leap Therapeutics
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Leap Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Leap Therapeutics and related companies.